OK432 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
278	Huge lymphatic malformation with cervicofacial lesion	2

278. Huge lymphatic malformation with cervicofacial lesion

---

Clinical trials : 19 /  Drugs : 22 - (DrugBank : 7) / Drug target genes : 5 - Drug target pathways : 63

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00010452 (ClinicalTrials.gov)	April 2000	2/2/2001	Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations	Treatment of Cystic Hygroma (Lymphangiomas) in Children- Picibanil(OK432) Sclerotherapy-Multicenter Trial	Lymphatic Malformations	Drug: picibanil	University of Iowa	NULL	Completed	6 Months	18 Years	Both	150	Phase 2/Phase 3	United States
2	NCT03427619 (ClinicalTrials.gov)	January 1, 1998	10/1/2018	OK432 (Picibanil) in the Treatment of Lymphatic Malformations	OK432 (Picibanil) in the Treatment of Lymphatic Malformations	Lymphatic Malformations	Drug: OK432	Richard JH Smith	NULL	Completed	6 Months	17 Years	All	701	Phase 4	United States